Two FOXM1 proteolysis-targeted chimeras (PROTACs) have been reported recently [78, 84] that degrade FOXM1 and inhibit breast and liver cancer cell proliferation and xenograft growth when dosed IV. Here, FOXM1 is linked to liver cancer.